Illumina (ILMN) Jumps 24.8% on Earnings Beat

Core Insights - Illumina, Inc. (NASDAQ:ILMN) experienced a significant stock increase of 24.78% to close at $123.54 after exceeding earnings guidance for Q3 and projecting a smaller revenue decline for fiscal 2025 [1][3]. Financial Performance - The company's net income fell by 79% to $150 million from $705 million, while revenues remained flat at $1.08 billion [2]. - Illumina's Q3 results surpassed the high end of guidance for revenue and earnings, driven by growth in the clinical segment, which is its largest market [2][3]. Future Projections - For fiscal year 2025, Illumina now expects revenues to decline by only 0.5% to 1.5% year-on-year, a revision from the previous upper range of 2.5% [3]. Company Overview - Illumina is a leading genomics company that provides DNA sequencing and array-based technologies for various sectors, including life sciences, oncology, and reproductive health [4].